IODIXANOL IN ABDOMINAL DIGITAL SUBTRACTION ANGIOGRAPHY - A RANDOMIZED, DOUBLE-BLIND, PARALLEL TRIAL WITH IODIXANOL AND IOHEXOL

The safety, tolerability and efficacy of iodixanol 270 mg I/ml were co mpared to those of iohexol 300 mg I/ml in a double-blind, randomized, parallel abdominal intra-arterial DSA phase III trial. Fifty-nine pati ents were included in the trial; 39 patients received iodixanol and 20 received iohexol. The mean volume of iodixanol administered was 235.8 ml (0.93 g I/kg b.w.) while the mean volume of iohexol was 254.7 ml ( 1.10 g I/kg b.w.). No differences in diagnostic information and radiog raphic density were apparent in spite of the difference in the concent ration of iodine. No serious adverse events occurred. Four patients (1 0%) in the iodixanol group and 2 (10%) in the iohexol group experience d adverse events. Eight percent of the injections of iodixanol promote d discomfort, compared to 12% of the injections of iohexol. An increas e in S-urea and S-creatinine was seen with both agents the first day a fter injection, but appeared to be less pronounced with iodixanol than with iohexol. Other serum tests revealed no changes of clinical impor tance. Both iodixanol and iohexol were found to be effective, safe and well tolerated contrast media for abdominal intra-arterial DSA.